ANIK
HealthcareAnika Therapeutics, Inc.
$9.47
+$0.12 (+1.28%)
Jan 5, 2026
Price History (1Y)
Analysis
Anika Therapeutics, Inc. is a company in the healthcare sector, operating within the drug manufacturers - specialty & generic industry. With a market capitalization of $136.57 million and annual revenues of $112.81 million, the company has a relatively small scale compared to other companies in its sector. The company's financial health indicates significant losses, with a net income of -$14,266,000 over the past four quarters. Its operating margin is -11.6%, and profit margin is -29.3%. Meanwhile, its gross margin stands at 55.3%. Anika Therapeutics has a negative return on equity (ROE) of -8.7% and a negative return on assets (ROA) of -3.5%. The company's balance sheet shows $57.99 million in cash and $24.51 million in debt, resulting in a debt-to-equity ratio of 16.69. Anika Therapeutics' valuation metrics include a forward P/E ratio of 36.42 and an EV/EBITDA of -27.64. The company's revenue growth has declined by 5.9% year-over-year, but its earnings growth rate is not available. Dividend information is not provided in the available facts section.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $136.57M
- P/E Ratio
- N/A
- 52-Week High
- $18.37
- 52-Week Low
- $7.87
- Avg Volume
- 143.35K
- Beta
- 0.46
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 288